Health & Beauty

On August 16, 17 departments including the National Health and Health Commission issued the "Guiding Opinions on Further Improving and Implementing Active Reproductive Support Measures" (hereinafter referred to as the "Opinions"), which for the first time clarified that assisted reproductive technology projects should be included in the payment of medical insurance funds according to procedures. scope. From the perspective of people in the medical service industry, assisted reproductive industry chain companies are expected to fully benefit from policy dividends and usher in new opportunities for industrial development.

Assisted reproductive technology is an important method for the treatment of infertility. It refers to the technology that uses medical aids to help infertile couples get pregnant, including artificial insemination (IUI), gamete transfer, and in vitro fertilization-embryo transfer (IVF-ET). The most widespread are artificial insemination and in vitro fertilization (IVF). With the continuous maturity of IVF technology and the improvement of people's living standards and educational levels, patients' acceptance of IVF has gradually increased.

At present, A-share companies in the assisted reproductive sector cover infertility treatment, assisted reproductive genetic technology, assisted reproductive medical services, and progesterone drugs.

In terms of ovulation induction related drugs, although most of them are imported from abroad, domestic technology is also relatively mature. For example, Livzon Group's product market share can reach 20%, and Xianju Pharmaceutical and Jinsai Pharmaceutical, a subsidiary of Changchun High-tech, have layouts.

In terms of PGT (pre-embedding genetic testing) diagnosis, companies such as Bekang Medical and BGI are in a stage of rapid development.

In terms of high-value consumables, market segments such as culture medium and seminiferous catheters are monopolized by overseas giants, and the import rate is as high as 95%. Domestic leading companies include Weituo Bio, Weigao Ruisheng, Heyun Medical, and Huanhao Technology , Pinzhi Medical, etc. are accelerating the layout.

The reporter noticed that medical institutions downstream of the assisted reproduction industry are still scarce resources. According to reports, my country's assisted reproductive market is largely controlled by state-owned hospitals and multinational pharmaceutical companies due to strict policy control and scarcity of licenses, resulting in a high degree of industry concentration.

There are also more and more companies actively deploying "three-child" related fields. Anke Biology stated on the interactive platform that the company has made strategic layouts in the fields of growth and development, assisted reproduction, precision medicine and other fields. In the field of assisted reproduction, a product line of diagnostic reagents has also been developed for male and female infertility detection.

Meditech stated on the interactive platform that its wholly-owned subsidiary, Queen Mary Hospital, is a specialized hospital focusing on the treatment of "test tube babies", and its current core competitiveness is reflected in the three major fields of reproductive medicine, gynecology and andrology. Sinopharm Hyundai introduced that at present, the company's products in the field of assisted reproduction mainly include raw materials urofollicle stimulating hormone, chorionic gonadotropin, and urinary gonadotropin. It is one of the main suppliers of related raw materials in China. In the future, the company will extend from the upstream and downstream industry chain, Planning and layout of the research and development of new formulations, related product field expansion, international market development and registration.